16 Apr 2015 17:48
16 April 2015
Silence Therapeutics plc
Additional listing
Silence Therapeutics plc, AIM: SLN, ('the Company'), announces that it has issued 1,036,848 new ordinary shares of 5p each ("Ordinary Shares") following the exercise of share options under the Employee Share Scheme.
Application has been made for the 1,036,848 Ordinary Shares issued to be admitted to trading on AIM ("Admission"). Admission is expected to take place on Wednesday, 22 April 2015. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
The total number of shares in issue, following admission, will be 53,134,957.
Enquiries:
Silence Therapeutics plc | +44 (0)20 3700 9711 |
Ali Mortazavi, CEO | |
Timothy Freeborn, Finance Director | |
Rozi Morris, Communications Manager | |
Canaccord Genuity Limited | +44 (0)20 7523 8350 |
Dr Julian Feneley/Cara Griffiths/Henry Fitzgerald-O'Connor |
About Silence Therapeutics (www.silence-therapeutics.com)
Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need. Silence's technology is currently in the clinic in a Phase 2a pancreatic cancer trial.